Adagio Therapeutics has filed for an initial public offering to support development of an antibody drug meant to treat or prevent infections from SARS-CoV-2 and, potentially, other coronaviruses as well.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,